FIELD: pharmaceutical chemistry.
SUBSTANCE: group of inventions includes a compound of formula (I), its pharmaceutically acceptable salts, enantiomers, dihydrate (S)-N-methyl-N-(6-methyl-2-((4aS,5aR)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-1H-benzo[d]imidazol-5-yl)-2-morpholinopropanamide, pharmaceutical composition and the use based on them. In formula (I), each R1 is independently H or F; R2 is either H or (C1-C4)alkyl; each R3 is independently H, F or (C1-C4)alkyl; R5 and R6 independently represent H; halogen; OH; CN; (C1-C6)alkyl; hydroxy(C1-C6)alkyl; (C1-C4)alkoxy(C1-C6)alkyl; (C1-C6)alkyl substituted with one, two or three F; (C1-C6)alkoxy; or (C1-C6)alkoxy substituted with (C1-C4)alkoxy; R4 is selected from 
or 
, each of which is optionally substituted with one or two substituents independently selected from oxo, (C1-C4)alkyl and hydroxy(C1-C4) alkyl.
EFFECT: benzimidazole derivatives exhibiting properties of ITK inhibitors.
26 cl, 7 dwg, 4 tbl, 56 ex
| Title | Year | Author | Number |
|---|---|---|---|
| C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | 2017 |
|
RU2716502C2 |
| BENZIMIDAZOLE DERIVATIVES AS ROR-GAMMA MODULATORS | 2017 |
|
RU2760366C2 |
| MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE | 2007 |
|
RU2459821C2 |
| PROPENOATE BETULIN DERIVATIVES | 2012 |
|
RU2613554C2 |
| 5-SUBSTITUTED INDAZOLE AS KINASE INHIBITORS | 2008 |
|
RU2487873C2 |
| BICYCLIC ARYL MONOBACTAM COMPOUNDS AND METHODS OF USING SAID COMPOUNDS FOR TREATING BACTERIAL INFECTIONS | 2017 |
|
RU2733402C2 |
| HUMAN IMMUNODEFICIENCY VIRUS REPLICATION INHIBITORS | 2019 |
|
RU2812128C2 |
| COMPOUNDS | 2016 |
|
RU2725616C2 |
| 2,6-SUBSTUTED-4-MONOSUBSTITUTED AMINO-PYRIMIDINES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | 2005 |
|
RU2417990C2 |
| AMINOTRIAZOLOPYRIDINES AND USING THEM AS KINASE INHIBITORS | 2009 |
|
RU2552642C2 |
